Cell Cycle and Biochemical Effects of PD 0183812

  title={Cell Cycle and Biochemical Effects of PD 0183812},
  author={D. Fry and D. C. Bedford and P. Harvey and A. Fritsch and P. Keller and Z. Wu and E. Dobrusin and W. Leopold and A. Fattaey and M. Garrett},
  journal={The Journal of Biological Chemistry},
  pages={16617 - 16623}
  • D. Fry, D. C. Bedford, +7 authors M. Garrett
  • Published 2001
  • Medicine, Biology
  • The Journal of Biological Chemistry
  • Progression through the G1 phase of the cell cycle requires phosphorylation of the retinoblastoma gene product (pRb) by the cyclin D-dependent kinases CDK4 and CDK6, whose activity can specifically be blocked by the CDK inhibitor p16INK4A. Misregulation of the pRb/cyclin D/p16INK4A pathway is one of the most common events in human cancer and has lead to the suggestion that inhibition of cyclin D-dependent kinase activity may have therapeutic value as an anticancer treatment. Through screening… CONTINUE READING
    91 Citations

    Paper Mentions

    The proposed study is a single-arm, multi-center, open-label phase II study of the combination of palbociclib and ibrutinib in patients with previously treated mantle cell lymphoma… Expand
    ConditionsB Cell Lymphoma, Mantle Cell Lymphoma
    Cyclin-dependent kinase inhibitors.
    • 69
    Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts.
    • 897
    • PDF
    Cyclin D-dependent kinases, INK4 inhibitors and cancer.
    • 729
    Regulators of G1 cyclin–dependent kinases and cancers
    • 112
    Small molecule inhibitors targeting cyclin-dependent kinases as anticancer agents
    • 63
    Biological characterization of 2-aminothiazole-derived Cdk4/6 selective inhibitor in vitro and in vivo
    • 10
    • Highly Influenced


    Characterization of novel inhibitors of cyclin-dependent kinases.
    • 42
    Requirement of Cyclin E-Cdk2 Inhibition in p16INK4a-Mediated Growth Suppression
    • 127
    • PDF
    Inhibition of cyclin-dependent kinase 4 (Cdk4) by fascaplysin, a marine natural product.
    • 131
    Anticancer drug targets: cell cycle and checkpoint control.
    • 367
    • PDF
    The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4.
    • A. Kubo, K. Nakagawa, +7 authors M. Kelley
    • Biology, Medicine
    • Clinical cancer research : an official journal of the American Association for Cancer Research
    • 1999
    • 69
    • PDF
    Identification of G1 kinase activity for cdk6, a novel cyclin D partner.
    • 800
    • PDF
    Cyclin D1 and human neoplasia.
    • 312
    • PDF
    Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer.
    • 749